GlassScriptPhysician profile
Charles Moussallem
NPI 1023318334
$5,494.12
in general payments reported to CMS, 2019-2025
29 companies · $1,172 in 2025
The $1,172 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $79.06 · 2021: $437 · 2022: $861 · 2023: $1,329 · 2024: $1,153 · 2025: $1,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,589 · Education: $64.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,589.29 |
| Education | $64.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $760.30 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $651.84 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $619.94 | 2021-2025 | Tavneos, Krystexxa, Parsabiv |
| Travere Therapeutics, INC. | $412.89 | 2023-2025 | Filspari |
| Opko Pharmaceuticals, LLC | $354.28 | 2019-2024 | Rayaldee |
| Fresenius USA Marketing, INC. | $345.92 | 2019-2025 | Velphoro, Optiflux, 2008t Bluestar Hemodialysis Machine |
| Novartis Pharmaceuticals Corporation | $316.78 | 2023-2025 | |
| Glaxosmithkline, LLC. | $276.58 | 2021-2024 | Benlysta |
| Vifor Pharma, INC. | $237.77 | 2019-2022 | |
| Novo Nordisk INC | $214.74 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Aurinia Pharma U.S., INC. | $197.41 | 2022-2024 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $190.42 | 2022-2025 | |
| Ardelyx, INC. | $185.73 | 2023-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $126.86 | 2023-2025 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $98.12 | 2022-2024 | Purified Cortrophin Gel |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.59 | 2023-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $81.90 | 2019-2024 | Jynarque |
| Janssen Pharmaceuticals, INC | $48.72 | 2024 | Xarelto |
| Akebia Therapeutics INC | $44.70 | 2019-2025 | Vafseo |
| Takeda Pharmaceuticals U.S.A., INC. | $39.64 | 2023 | Gattex |
| Cormedix INC. | $30.56 | 2024 | Defencath |
| Vantive US Healthcare LLC | $24.33 | 2025 | Renal - Pd |
| Daiichi Sankyo INC. | $23.28 | 2019 | |
| Alexion Pharmaceuticals, INC. | $21.70 | 2024 | Ultomiris |
| Abbvie INC. | $21.63 | 2021 | |
| Bard Peripheral Vascular, INC. | $20.99 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.30 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $17.91 | 2023 | |
| Nxstage Medical, INC. | $16.29 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Moussallem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.